Drug reference
Thyrotoxicosis (pre-operative) ▶BY MOUTH USING ORAL SOLUTION ▶Adult: 0.1–0.3 mL 3 times a day DOSE EQUIVALENCE AND CONVERSION ▶Doses based on the use of an aqueous oral solution containing iodine 50 mg/mL and potassium iodide 100 mg/mL.
PDF page 837
Not for long-term treatment
PDF page 837
Conjunctivitis. depression (long term use). erectile dysfunction (long term use). excessive tearing. headache. hypersensitivity. increased risk of infection. influenza like illness. insomnia (long term use). rash. salivary gland pain
PDF page 837
Neonatal goitre and hypothyroidism.
PDF page 837
Stop breast-feeding. Danger of neonatal hypothyroidism or goitre. Appears to be concentrated in milk.
PDF page 837
For oral solution, dilute well with milk or water.
PDF page 837
Forms available from special-order manufacturers include: oral solution 9.2 Hypothyroidism Thyroid hormones Overview Thyroid hormones are used in hypothyroidism (myxoedema), and also in diffuse non-toxic goitre, Endocrine system Hashimoto’s thyroiditis (lymphadenoid goitre), and thyroid carcinoma. Neonatal hypothyroidism requires prompt treatment for normal development. Levothyroxine sodium below (thyroxine sodium) is the treatment of choice for maintenance therapy. In infants and children with congenital hypothyroidism and juvenile myxoedema, the dose of levothyroxine sodium should be titrated according to clinical response, growth assessment, and measurements of plasma thyroxine and thyroid-stimulating hormone. Liothyronine sodium p. 817 has a similar action to levothyroxine sodium but is more rapidly metabolised and has a more rapid effect. Its effects develop after a few hours and disappear within 24 to 48 hours of discontinuing treatment. It may be used in severe hypothyroid states when a rapid response is desired. Liothyronine sodium by intravenous injection is the treatment of choice in hypothyroid coma. Adjunctive therapy includes intravenous fluids, hydrocortisone p. 713, and treatment of infection; assisted ventilation is often required. Advanced Pharmacy Services Patients with thyroid disorders may be eligible for the Medicines Use Review service provided by a community pharmacist. For further information, see Advanced Pharmacy Services in Medicines optimisation p. 18. THYROID HORMONES
PDF pages 837, 838
0.1–0.3 mL 3 times a day
First-line fragment. Read the complete Indications and Dose section above.
PDF page 837
